8-K: Lunai Bioworks Secures $11.7M ATM Equity Offering

Lunai Bioworks, Inc. entered into an At-the-Market Sales Agreement with Dawson James Securities, Inc. to offer and sell up to $11.70 million of common stock.

Summary

• Lunai Bioworks, Inc. (the Company) entered into an At-the-Market Sales Agreement (the Sales Agreement) with Dawson James Securities, Inc. (the Sales Agent) on December 2, 2025.
• The Sales Agreement allows the Company to offer and sell shares of its common stock, par value $0.0001 per share, with an aggregate offering price of up to $11.70 million.
• Sales of common stock will be made from time to time through the Sales Agent as the Company's sales agent, in transactions deemed at-the-market offerings, including on the Nasdaq Capital Market.
• The Sales Agent is entitled to compensation of 3.0% of the gross proceeds from the sales of any shares.
• The Company is not obligated to sell any shares and may suspend or terminate sales at any time upon notice to the Sales Agent.
• The Sales Agreement was made pursuant to the Company's Registration Statement on Form S-3 (File No. 333-282898), which became effective on November 6, 2024.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure financing, which is generally positive for operational flexibility. However, the potential for shareholder dilution and the absence of specific positive operational updates temper the overall sentiment to moderately positive.

Positives

• Provides the Company with flexible access to capital, allowing it to raise up to $11.70 million as needed.
• The 'at-the-market' nature of the offering allows for sales to be made opportunistically, potentially minimizing market impact compared to a traditional underwritten offering.

Negatives

• The offering will result in dilution for existing shareholders as new common stock is issued.
• A 3.0% commission to the Sales Agent reduces the net proceeds received by the Company from the offering.

Risks

• Ability to obtain and maintain necessary regulatory approvals for products and operations.
• Impact of general economic conditions on the Company's business.
• Fluctuations in consumer demand for the Company's products and services.
• Challenges related to entering into and growing new business lines.
• The competitive environment in the Company's industry.
• Risks and uncertainties detailed in the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings.
• Actual results may differ materially from forward-looking statements due to known and unknown risks and uncertainties.

Future Outlook

The Company's forward-looking statements include expectations regarding future revenue growth potential of its subsidiaries, the timeline for commercializing its BE-Smart Esophageal Cancer Test, future liquidity events, success in collecting accounts receivables, and its ability to transition into a consumer products company. These statements are subject to various risks and uncertainties.

Management Comments

• Management believes that these forward-looking statements are reasonable as and when made.

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential dilution of existing shareholdings as new common stock is issued under the ATM program.
• Company Operations: Increased capital availability could support strategic initiatives, research and development, and general corporate purposes, as described in the prospectus's 'Use of Proceeds' section.

Next Steps

• The Company may, from time to time, offer and sell shares of its common stock through the Sales Agent under the At-the-Market Sales Agreement.
• The Company will continue to comply with SEC filing requirements related to the offering and its ongoing operations.

Key Dates

Keywords

Lunai Bioworks, LNAI, At-the-Market, ATM, Equity Offering, Common Stock, Capital Raise, Dawson James Securities, SEC Filing, Form 8-K, Nasdaq Capital Market, Dilution